AnBogen has received the Impact Award at the 2025 NBRP Demo Day Pitch Competition.

Selected among 30 innovative biotech companies and 16 finalists, AnBogen was recognized as one of the top five award-winning companies at this prestigious event.

Our Chief Medical Officer, Dr. Mark Horng, presented a compelling pitch on ABT-301, our selective HDAC1/2/3 inhibitor designed to reshape the tumor immune microenvironment by enhancing CD8+ T cells and reducing MDSCs—targeting the 95% of mCRC patients with MSS tumors who currently lack effective immunotherapy options.

Thank you to the NBRP team and judging panel for this meaningful recognition. We' re proud to be part of Taiwan's dynamic biotech ecosystem and remain dedicated to advancing innovation in oncology.